ERYtech Pharma Reinforces its Supervisory Board and its Scientific Board

• Sven Andréasson, MBA. Permanent representative of Galenos SPRL, Independent Director, he is the CEO of Beta-Cell NV in Brussels. He has longstanding experience in the international biotech and pharmaceutical industries. This includes time spent as President and CEO for Active Biotech AB (publ.) 1999 – 2008 and as President and Vice President of mainly Swedish, Belgian, French and German companies within the Pharmacia Corporation 1976 - 1999. Sven Andréasson has an MSc in business administration and finance from the Stockholm School of Economics. He is chairman of Unibioscreen SA (Brussels) and Operations Leadership Oil AB (Stockholm). He is also an independent board member of TiGenix (publ.) - (Leuven).
• Dr. Alain Munoz, M.D. AGF Private Equity representative, Former Fournier VP R&D and BD, Former Sanofi. Dr. Alain Munoz is an MD in Cardiology and Anaesthesiology, former resident, and former Chief Clinician at the Hôpitaux de Montpellier. He is also a former member of the scientific committee of the French Drug Agency (Agence du Médicament). He currently acts as an entrepreneur developing his own projects. He is a board member of several biotechnology companies and an adviser to investors. Dr Munoz is also member of several Boards, such as: Vivalis (Fr), Novagali Chairman (Fr), Zealand (DK), Auris médical (SW).

The new members of the Scientific Board:

• Pr. Wolfgang R. Mayr, M.D. Currently Medical Counselor for Transfusion Medicine at the Austrian Red Cross, he has well established experience and qualifications as a medical specialist in blood group serology, transfusion medicine and immunology. Pr Mayr was President of the 26^th Congress of the International Society of Blood Transfusion in 2000 and is currently an active member of several international scientific and medical societies.
• Pr. Eric Raymond, M.D. Ph.D. Head of the Oncology Department at Beaujon-Bichat University Hospital, Paris – France, he has highly regarded expertise in Oncology in clinical and pre-clinical approaches. Pr. Raymond has published more than 100 articles and is a member of several international societies of experts in the field of oncology.
• Dr. Philip L. Lorenzi, Ph.D. Currently Supervisor of Laboratory & Research in the Department of Bioinformatics & Computational Biology at M.D. Anderson Cancer Center, Houston, Texas, USA, he is an expert in pharmacogenomics, systems pharmacology, and translational research, with a focus on biomarker identification related to extending L-asparaginase chemotherapeutic utility.

Dr Yann Godfrin, CEO and Co-Founder of ERYtech Pharma said "Today, our activity includes all departments from Research to Clinical Development through GMP. The nomination of these new, extremely experienced members comes within the framework of ERYtech Pharma’s continuum of excellence."

Pierre-Olivier Goineau, EVP and Co-Founder of ERYtech Pharma, said "Having Alain and Sven is a major asset for ERYtech Pharma both in continuing its internationalization and in preparing the commercial launching of GRASPA^®."

Yann Godfrin, Pierre-Olivier Goineau and all the board members took the opportunity to warmly thank François MICELI for his Chairmanship of the Board of ERYtech Pharma since 2005.

About GRASPA®

GRASPA^® is a new enzyme formulation of L-asparaginase with a safer and broader range of clinical uses compared to existing forms due to the entrapment and protection of the enzyme inside the homologous red blood cell. GRASPA^®’s (encapsulating L-asparaginase in red blood cells) interest lies in overcoming all existing limitations associated with conventional L-asparaginase through longer efficacy, better compliance, reduced dosage and an increased safety profile; making it satisfactory for every ALL patients, even high risk ones (hypersensitive, elderly patients), or patients with neutralising antibodies.

L-asparaginase is a critical and irreplaceable component of combination chemotherapy for ALL and has been used in the clinic for over 30 years. The enzyme depletes the plasmatic amino acid asparagine, which leukaemia cells require to continue their rapid, malignant growth. While normal cells are able to make a sufficient amount of asparagine internally, leukaemia cells cannot. Infusion of L-asparaginase destroys the external source of asparagine, which starves leukaemia cells of this amino acid and leads to cellular death.

About ERYtech Pharma

ERYtech Pharma is a specialty pharma company developing innovative therapeutic solutions based on its proprietary technology and expertise in the physiological properties of erythrocytes. The company addresses serious pathologies, orphan indications or sub-populations of patients, particularly in the fields of haematology, cancer and metabolic diseases.

GAIA Communication
Cathy CLEMENT
+33 (0)1-3082-6665
cathy.clement@gaiacommunication.fr
or
ERYtech Pharma - US Office
contact-usa@erytech.com
or
Other contacts:
contact@erytech.com
or
Website
www.erytech.com